Introduction
============

One of the top priorities in therapeutics is pain control and in spite of the recent advances in clinical investigation of new therapeutic agents, pain relief is still a significant challenge. The reasons include difficulties of correctly evaluating pain, underestimation of patients' pain, misconceptions about analgesic use and side effects, gaps in pain management process, and lack of acute pain service.[@b1-lra-3-093] Local anesthetics (LAs) are among the different classes of pharmacological compounds used to eliminate pain. LAs are small molecules that could be easily eluted from the site of administration, thus limiting the analgesic property.

Cocaine is the first compound that was used as a "numbing agent" in the early 1500s. However, it is usually associated with the central nervous system and cardiovascular system toxicity. Presently, most of the synthetic LAs are structurally related to cocaine but with reduced toxicity. LA works by cutting the signal of nerve impulses in nerve cell membranes through the shutting of voltage-gated Na^+^ channels. The degree of numbness from a certain concentration will depend on how the nerve is stimulated and the resting membrane potential.[@b2-lra-3-093] Clinical LAs belong to one of the two classes: amino esters ([Figure 1A](#f1-lra-3-093){ref-type="fig"}) and amino amide ([Figure 1B](#f1-lra-3-093){ref-type="fig"}). Amino ester LAs were developed in early 1900s. Ester-based LAs are hydrolyzed and inactivated by plasma esterase, primarily plasma cholinesterase. Therefore, they are always associated with low potency, slow onset, and short therapeutic duration.[@b2-lra-3-093] Amino amide LAs became popular and many of this class of drugs were developed by 1970s. Amide-based LAs are degraded by hepatic endoplasmic reticulum, leading to a slower removal from the body and higher concentration in the plasma. With the introduction of bupivacaine, accidental overdose was often fatal and responded poorly to conventional resuscitation.[@b2-lra-3-093],[@b3-lra-3-093] This had led to a search for long-acting LAs with improved therapeutic margins and reduced toxicity. Trachez et al and Zapata-Sudo et al demonstrated that S(−) enantiomer of bupivacine is more potent[@b4-lra-3-093] and less toxic[@b5-lra-3-093] than R(+) enantiomer leading to the selection of S(−) enantiomers of ropivacine and levobupivacine as safer alternatives to bupivacine.

High toxicity of LA due to over dosage and strong clinical requirements have triggered the interest in the field on controlled release of LA. One of the primary objectives in the design of a controlled release system is the controlled delivery of therapeutics to the site with an optimal release rate. From here, two major areas have evolved: (1) design of good carriers to protect and deliver the therapeutics to the site of action and (2) development of a sustained drug formulation for a slow and long lasting effect.[@b6-lra-3-093] The release of these drugs will be controlled by desorption, diffusion, erosion, or a combination of these factors.[@b7-lra-3-093] One approach to prolong the effect of analgesia is to complex the LA with drug delivery vehicles. The larger carriers will remain at the injection site for a longer period of time with a gradual release of the LA. Liposomes,[@b8-lra-3-093]--[@b11-lra-3-093] cyclodextrins,[@b12-lra-3-093] microspheres,[@b13-lra-3-093]--[@b15-lra-3-093] hydrogels,[@b16-lra-3-093] and nanospheres[@b6-lra-3-093],[@b17-lra-3-093]--[@b20-lra-3-093] could encapsulate the LA for controlled delivery, prolonged anesthetic effect, and reduced toxicity. From these various types of controlled delivery systems, depending on the end-use requirements, the most popular choice is nanospheres followed by microspheres and hydrogels.[@b21-lra-3-093]

In this review, different methods of nanogel synthesis and an overview of drug release from nanogel-based delivery vehicles will be described and discussed.

Synthesis technique
===================

Current approaches used for the preparation of nanogels can be classified into four categories: (1) polymerization of monomers in a homogeneous phase or in a microscale or nanoscale heterogeneous environment; (2) physical self-assembly of interactive polymers; (3) cross-linking of preformed polymers; and (4) template-assisted nanofabrication of nanogel particles. In this section, we will discuss these methods, where the synthesis technique being employed is typically dictated by the desired application and types of study being performed.

Surfactant-free emulsion polymerization or precipitation polymerization is a versatile technique for synthesizing stimuli-responsive nanogels. Nanogels synthesized by this method are formed by homogeneous nucleation of water-soluble monomers, which results in the formation of a colloidal suspension of the growing polymer, and the charge imparted by the initiator stabilizes the gels. This method is versatile from the standpoint of particle size control. To synthesize smaller nanogels, the precursor particles must be stabilized earlier in the reaction, where an ionic surfactant can be added to impart colloidal stability. Similarly, larger particles can be obtained by decreasing the surfactant concentration.[@b22-lra-3-093] Peppas and coworkers[@b23-lra-3-093] synthesized a suspension of nanospheres composed of poly (ethylene glycol) (PEG)-grafted poly (methacrylic acid) (PMA) in water using the precipitation polymerization method. Thermoresponsive poly (*N*-isopropylacrylamide) (PNIPAM) nanogels with narrow size distribution were first synthesized by Pelton and Chibante,[@b24-lra-3-093],[@b25-lra-3-093] where all the monomers and cross-linker are dissolved in water.

Precipitation polymerization is best for materials that are hydrophobic, so that they can readily attach to the collapsed precursor particle and is useful only for materials that are stable at high temperatures, and hence it cannot be used to incorporate biological macromolecules. Thus, if a hydrophilic comonomer is to be copolymerized, only a certain weight percentage can be incorporated.[@b22-lra-3-093] To overcome these drawbacks, inverse microemulsion polymerization is used, where an aqueous solution of all the monomers is added to an appropriate amount of oil and surfactant to produce a thermodynamically stable microemulsion. Various drugs, DNA, and cells are physically incorporated into these aqueous microemulsions, which are then cross-linked with appropriate cross-linking agents. The resulting cross-linked nanogels are prepared by dispersion in organic solvents, and then purified by precipitation, centrifugation, washing (usually with organic solvents, such as isopropanol), and lyophilization. Several reports have demonstrated the synthesis of hydrophilic or water-soluble particles comprising of poly (2-hydroxyethyl methacrylate) (PHEMA),[@b26-lra-3-093] polyacrylic acid (PAA),[@b27-lra-3-093] polyacrylamide (PAAm),[@b26-lra-3-093] PNIPAM,[@b28-lra-3-093]--[@b30-lra-3-093] and polyaniline.[@b31-lra-3-093] These nanoparticles can be either hollow and zwitterionic or core--shell nanocapsules with hydrophobic shell and hydrophilic interior. Labile bonds are frequently introduced into the nanogels during polymerization to make them degradable and facilitate drug release.[@b32-lra-3-093]--[@b36-lra-3-093] Matyjaszewski and coworkers[@b35-lra-3-093],[@b36-lra-3-093] used the atom transfer radical polymerization (ATRP) performed in an inverse microemulsion system to synthesize stable biodegradable nanogels comprising of water-soluble polymers with a disulfide-functionalized cross-linker.

Nanogels can also be formed using the physical self-assembly of polymers involving a mixture of amphiphilic copolymer and a therapeutic agent in an organic solvent via membrane dialysis or from direct complexation between cationic copolymers and genes or proteins in an aqueous solution through noncovalent interactions, such as Van der Waals, hydrogen bonding, stereocomplexation, charge transfer, and polyelectrolyte complexation. During the self-assembly process, small molecular drugs and macromolecular therapeutics, such as genes and proteins, can be incorporated into the micellar nanostructures. The most widely used selfassociating polymers are amphiphilic block copolymers that possess hydrophobic and hydrophilic blocks that can self-assemble in selective solvents to form submicron-size micelles (nanogels). These amphiphilic polymers can be synthesized via living radical polymerization (LRP) techniques (eg, ATRP, reversible addition -- fragmentation chain transfer \[RAFT\], and nitroxide-mediated polymerization \[NMP\]). The micellization of amphiphilic block copolymers can be tailored by changing the block nature, block lengths, composition, or architecture.[@b37-lra-3-093]--[@b39-lra-3-093] In addition, external parameters, ie, change in temperature or solvent or addition of additives, such as electrolytes and cosolvents, provide extra degrees of freedom to tune the micellar behavior of the amphiphilic block copolymers.[@b40-lra-3-093]--[@b44-lra-3-093] Moreover, the chemistry of the surface can be manipulated for the conjugation of a targeting signal that can recognize specific tissues or cells. The functionalities of the core of nanogels can be tuned using specific chemical approaches to improve the drug-loading capacity. The molecular compositions of the copolymers used to form the nanogels can be controlled through LRP approaches to achieve nanostructures with narrow size distribution.

In addition to the above two polymerization methods, covalent cross-linking of preformed polymer chains provides excellent opportunities for producing functional nanogels with large pore sizes for drug delivery.[@b45-lra-3-093] In particular, it was used to synthesize the first cross-linked cationic nanogel for polynucleotide delivery.[@b46-lra-3-093] In this case, a doubly activated PEG was conjugated to a branched polyethylenimine (PEI) in an oil in water emulsion (dichloromethane in water) followed by evaporation of the solvent *in vacuo* and maturation of the nanogel in an aqueous solution. Cationic PEI containing nanogels of 80--200 nm diameter were also obtained by the photo-Fenton reaction in aqueous media.[@b47-lra-3-093],[@b48-lra-3-093] Small (40--45 nm), nontoxic cross-linked pullulan nanogels were prepared in the reverse micellar system (aerosol OT/hexane).[@b49-lra-3-093],[@b50-lra-3-093] The cross-links that connect the polymeric chains in such nanogels can be made degradable to reduce their toxicity. For example, a biodegradable segmented PEI connected by disulfide linkers was used to prepare cationic nanogels for polynucleotide delivery,[@b51-lra-3-093] and hyaluronic acid (HA) nanogels containing biodegradable disulfide linkages were prepared by the inverse water in oil emulsion method.[@b52-lra-3-093] An interesting type of cross-linked nanogels containing DNA was obtained by mixing thiol-functionalized 6-arm-branched PEG and DNA in dimethyl sulfoxide, which produced particles of 100 nm diameter and subsequently cross-linked by oxidation to obtain DNA-loaded biodegradable nanogels.[@b53-lra-3-093]

Combining the controlled self-assembly of polymeric micelles and cross-linking techniques provided opportunities for the control of the spatial distribution of polymeric chains at the nanolength scale. For example, Wooley and coworkers[@b54-lra-3-093]--[@b58-lra-3-093] have chemically cross-linked the shell layers of polymeric micelles to obtain various shell-cross-linked nanoparticles with morphologies, such as spheres, rods, and even toroids. In another study, PEI was cross-linked to micelles of doubly activated Pluronic^®^ triblock copolymer in aqueous solution to produce nanogels with a hydrophobic poly (*p*-phenylene oxide) (PPO) core surrounded by a swollen cross-linked PEI and a PEG shell.[@b59-lra-3-093] Lee et al[@b60-lra-3-093] photo-cross-linked the polymeric micelles of poly(D,L-lactic acid)-*b*-PEG-*b*-poly(D,L-lactic acid) with acrylate end groups, resulting in the formation of nanogels containing self-assembled hydrophobic domains of micelles with insoluble poly(D,L-lactic acid) cores, which could be loaded with a hydrophobic anticancer drug.

Finally, DeSimone and coworkers[@b61-lra-3-093] developed a novel imprint photolithographic technique, particle replication in nonwetting templates (PRINT), for the fabrication of nanogels. They used nonwetting elastomeric molds of a low-surface-energy perfluoropolyether network prepared on patterned silicon templates by photochemical cross-linking of dimethacrylate-functionalized perfluoropolyether oligomers. The nonwetting molds eliminate the formation of a residual interconnecting film between the molded objects, thus producing monodispersed, shape-specific nanoparticles from an extensive array of organic precursors. This method enables strict control over the particle size, shape, composition, and surface functionality and permits the loading of delicate cargos, including pharmaceutical drugs and biomacromolecules. For example, monodispersed 200-nm-diameter PEG-based swellable particles were fabricated with the PRINT method by UV-induced copolymerization of several vinyl monomers, such as PEG triacrylate, PEG monomethyl ether monomethacrylate, and *p*-hydroxystyrene.[@b62-lra-3-093]

Nanogel systems as carriers
===========================

Parenteral route is the only approach to administer drugs, as this will ensure the quickest onset of the therapeutic product. From the work of Lee et al,[@b63-lra-3-093] injections made with nanogels are less painful when compared with cosolvent-based formulation. High blood circulation time could be achieved due to the size of the nanogels, which is very important to extend the therapeutic efficacy of the LA. Nanogels exhibit excellent thermodynamic stability, high solubilization capacity, low viscosity, and ability to withstand sterilization techniques, and these properties make nanogels as interesting delivery systems.[@b64-lra-3-093] Most importantly, after the encapsulation of LA into the nanospheres, the toxicity effect is greatly reduced as shown by the work of Moraes et al using poly(DL-lactide-*co*-glycolide) nanospheres encapsulated with either bupivacaine[@b17-lra-3-093] or ropivacaine.[@b18-lra-3-093] In both the cases, after encapsulation of the LA, there was a significant improvement in the viability of 3T3 cells ([Figure 2](#f2-lra-3-093){ref-type="fig"}).

Drug -- nanogel interactions
----------------------------

There are 2 goals that should be satisfied in the design of a delivery system:[@b65-lra-3-093] (1) efficient binding of drugs to the polymeric matrix and release of the drugs in a controlled manner and (2) ability to release through a local or externally applied trigger by changing the binding affinity between the drug and the polymeric matrix. Since most of the LAs possess secondary or tertiary amines, electrostatic interaction is the dominant driving force, depending on the pH of the solution and p*K*a of the LA. Therefore, a clear understanding on the interaction between the LA and the nanogel is critical for the development of an efficient drug delivery system. Procaine hydrochloride (PrHy; a LA drug of the amino ester group) loaded into methacrylic acid--ethyl acrylate (MAA--EA) nanogels through hydrophobic and hydrogen bonding ([Figure 3](#f3-lra-3-093){ref-type="fig"}) showed a higher release at a higher pH ([Figure 4](#f4-lra-3-093){ref-type="fig"}).[@b66-lra-3-093] At a higher pH, the acid on the nanogels will be deprotonated, thus increasing the osmotic pressure and swelling the nanogels. This will promote the release of PrHy through the increase in porosity.[@b20-lra-3-093] Different kinds of interactions will result in a different release profile, which will be important for the design of a delivery carrier, where drug release can be triggered by changing the pH. First, the results demonstrated the viability of tuning the release profiles of drug from a pH-responsive nanogel system. The proportion of drug released can be controlled by manipulating the pH of the environment. Hence, it is possible to design a pH-dependent gradient release drug delivery system, such that the active drugs could be released from the carrier in different regions of the physiological environment that possess different pH conditions. This will extend the therapeutic range of active drugs and ensure that the targeted areas receive the right dosage of drugs. Second, the interaction between the drug and delivery carriers controls the release profiles and the effective therapeutic range of drug carriers. Therefore, it is possible to design a drug delivery system with enhanced interaction in order to have a better control of release behavior.[@b20-lra-3-093]

Size effect on the release of drugs
-----------------------------------

Histological studies showed that particles with a size of 100 nm could diffuse through the submucosal layers, whereas larger-sized particles (500 nm--10 μm) were found to concentrate within the epithelial tissue linings.[@b67-lra-3-093] Due to the high surface area-to-volume ratio, the release of hydrophilic LA will be rapid, that is indicated by the initial burst release. High initial burst release has been observed for poly(DL-lactide-*co*-glycolide) nanopaticles,[@b19-lra-3-093],[@b68-lra-3-093] chitosan nanoparticles,[@b69-lra-3-093] and PNIPAM-*co*-acrylic acid hydrogels in the submicron range.[@b70-lra-3-093] A simple approach in addressing the problem of initial burst of nanogels was proposed by our group using the layer-by-layer (LBL) technique.[@b71-lra-3-093] LBL is a simple technique of coating alternating layers of oppositely charged polyelectrolyte onto a surface. However, the coating must not be too stable, as this will impact the effectiveness of the coated particles as a vehicle for drug delivery. Permeability will be reduced if the coating is too stable, resulting in a continuous slow release of the drugs.[@b71-lra-3-093] With more polyelectrolyte layers, the more accessible PrHy molecules have to diffuse through the polyethylene (PE) layers, therefore mitigating the burst release phenomenon ([Figure 5](#f5-lra-3-093){ref-type="fig"}).[@b71-lra-3-093]

Effect of drug-loading content on drug release
----------------------------------------------

From the work of Görner et al,[@b6-lra-3-093] it is shown that size and drug loading do have an effect on the mass of drugs released per milligram of nanospheres and the time to attain equilibrium release. Larger particles will result in higher mass of drugs released and longer time to achieve equilibrium. Tan et al[@b66-lra-3-093] have also shown that with a higher drug loading content of PrHy, the rate and amount of drugs released will be greatly affected ([Figure 6](#f6-lra-3-093){ref-type="fig"}). As a result, we have learned that the drug release rate of the encapsulated drugs is highly dependent on the state (crystalline or dispersed).

Conclusion
==========

The use of LA could be limited by the relatively short therapeutic action and systemic toxicity related to high drug plasma concentration as a result of fast systemic uptake. Improvement of regional administration of LAs could be achieved by incorporating them into drug delivery systems. Nanogels are probably one of the better candidates due to the lesser pain during injection and longer blood circulation time. However, designing a perfect candidate would require one to have a thorough knowledge of the interaction between the drug and the carrier and the effect of size and drug loading on drug release.
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![Chemical structure for (**A**) amino ester and (**B**) amino amide.](lra-3-093f1){#f1-lra-3-093}

![(**A**) Cytotoxic effects of bupivacaine (BVC), poly(DL-lactide-*co*-glycolide) nanospheres (PLGA-NSs), and PLGA-NS:bupivacaine at 0.25% and 1.25% on Balb/c 3T3 cells incubated for 24 hours at 37°C and 5% CO~2~, as evaluated by MTT reduction test[@b17-lra-3-093] and (**B**) cytotoxic effects of ropivacaine (RVC), PLGA-NS, and PLGANS: ropivacaine at 0.25 and 1.25 mg/mL on Balb/c 3T3 cells incubated for 24 hours at 37°C and 5% CO~2~, as evaluated by MTT reduction test.[@b18-lra-3-093]](lra-3-093f2){#f2-lra-3-093}

![(**A**) Differential enthalpy curves for titrating 600 mM procaine hydrochloride (PrHy) into 0.1 wt% HASE 20--80--1 at varying degrees of neutralization: *α* = 0.3 (□), *α* = 0.5 (Δ), and *α* = 1 (⋄) and (**B**) differential enthalpy curves for titrating 600 mM PrHy into fully neutralized (*α* = 1) 0.1 wt% HASE 20--80--1 at varying temperatures: 25°C (⋄), 40°C (□), and 50°C (Δ).[@b20-lra-3-093]](lra-3-093f3){#f3-lra-3-093}

![*In vitro* release profile of procaine hydrochloride from 0.1 wt% HASE 50--50--4 at varying pH: pH 5 (□), pH 6 (Δ), pH 7 (⋄), and pH 8 (○).[@b20-lra-3-093]](lra-3-093f4){#f4-lra-3-093}

![Experimental release profiles for 0.1 wt% HASE 50--50--4 grafted with PEGMA and polyelectrolyte-coated HASE 50--50--4 grafted with PEGMA nanogels in 100 mL of 10 mM NaCl at pH 7.4 (symbols) and theoretical fit of the mathematical model taking into account drug diffusion and chain relaxation (solid lines).[@b71-lra-3-093]](lra-3-093f5){#f5-lra-3-093}

![Experimental *in vitro* release profile of procaine hydrochloride from 0.1 wt% HASE 50--50--4 at varying initial drug loading: 0.009 M (□), 0.011 M (Δ), 0.017 M (⋄), 0.022 M (○), and 0.051 M (+) and theoretical fit of the mathematical model taking into account drug diffusion and chain relaxation (solid lines).[@b66-lra-3-093]](lra-3-093f6){#f6-lra-3-093}
